|
N-803 Clinical Trials
6 actively recruiting trials across 3 locations
Also known as: ALT-803, Anktiva
Pipeline
Phase 2: 3Phase 3: 1Phase 1/2: 2
Top Sponsors
- National Cancer Institute (NCI)3
- ImmunityBio, Inc.3
Indications
- Cancer6
- Stage IV Squamous Cell Carcinoma of the Head and Neck1
- Stage III Squamous Cell Carcinoma of the Head and Neck1
- Stage II Squamous Cell Carcinoma of the Head and Neck1
- Carcinoma of Endometrium1
Bethesda, Maryland3 trials
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
National Institutes of Health Clinical Center
Phase 2
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Institutes of Health Clinical Center
Phase 1/2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center
Phase 1/2
El Segundo, California2 trials
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Chan Soon-Shiong Institute for Medicine
Phase 2
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Chan Soon-Shiong Institute for Medicine (CSSIFM)
Phase 2
Springdale, Arkansas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.